tradingkey.logo
搜尋

ANI Pharmaceuticals Inc

ANIP
添加自選
78.010USD
-1.570-1.97%
收盤 05/15, 16:00美東報價延遲15分鐘
1.75B總市值
18.96本益比TTM

ANI Pharmaceuticals Inc

78.010
-1.570-1.97%

關於 ANI Pharmaceuticals Inc 公司

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc簡介

公司代碼ANIP
公司名稱ANI Pharmaceuticals Inc
上市日期May 04, 2000
CEOLalwani (Nikhil Suresh)
員工數量897
證券類型Ordinary Share
年結日May 04
公司地址210 Main Street West
城市BAUDETTE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編56623
電話12186343500
網址https://www.anipharmaceuticals.com/
公司代碼ANIP
上市日期May 04, 2000
CEOLalwani (Nikhil Suresh)

ANI Pharmaceuticals Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.85K
-12.61%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
--
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%

收入明細

單位: USD更新時間: 4月6日 週一
單位: USD更新時間: 4月6日 週一
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%
地區USD
名稱
營收
佔比
United States
852.44M
96.50%
International
30.92M
3.50%
業務
地區
業務USD
名稱
營收
佔比
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%

股東統計

更新時間: 5月10日 週日
更新時間: 5月10日 週日
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
其他
75.58%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
其他
75.58%
股東類型
持股股東
佔比
Investment Advisor
42.89%
Investment Advisor/Hedge Fund
23.64%
Hedge Fund
20.43%
Research Firm
6.41%
Individual Investor
5.68%
Private Equity
4.46%
Pension Fund
2.51%
Corporation
1.92%
Bank and Trust
1.50%

機構持股

更新時間: 4月1日 週三
更新時間: 4月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2026Q1
555
23.15M
101.74%
+57.73K
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
2.45M
10.91%
+103.61K
+4.42%
Dec 31, 2025
Meridian Venture Partners
1.01M
4.53%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
727.20K
3.24%
+15.50K
+2.18%
Dec 31, 2025
Millennium Management LLC
539.66K
2.41%
+474.42K
+727.14%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
487.67K
2.18%
-17.76K
-3.51%
Dec 31, 2025
Soleus Capital Management, L.P.
486.24K
2.17%
+146.00K
+42.91%
Dec 31, 2025
Tang Capital Management, LLC
481.44K
2.15%
+163.94K
+51.63%
Dec 31, 2025
Deep Track Capital LP
477.68K
2.13%
+27.68K
+6.15%
Dec 31, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
查看更多
Invesco Pharmaceuticals ETF
佔比2.63%
State Street SPDR S&P Pharmaceuticals ETF
佔比2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
佔比1.63%
Innovator IBD Breakout Opportunities ETF
佔比1.38%
Innovator IBD 50 Fund ETF
佔比1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比0.98%
Invesco S&P SmallCap Health Care ETF
佔比0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
佔比0.92%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.67%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI